CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $127.32M, lower than 95% of all stocks globally
- PositionReturn on equity is -187.1%, lower than 95% of its Biotechnology peers (median -22.3%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
127.32MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.74xvs all stocks
52-Week Change
-61.48%vs all stocks
Market Capitalization
127.32MUSDvs all stocks (USD)
Enterprise Value
63.74MUSDvs all stocks (USD)
Forward P/E
-1.01xvs Biotechnology peers
Price to Book (MRQ)
2.85xvs Biotechnology peers
Enterprise to EBITDA
-0.3090xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-73.85%vs Biotechnology peers
Return on Equity (TTM)
-187.11%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-206.19MUSDvs all stocks (USD)
Net Income (TTM)
-212.74MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-180.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-99.42MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-241.16MUSDvs all stocks (USD)
Pre-tax Income
-236.80MUSDFY2025 · Dec 31, 2025Income Tax Expense
130.00KUSDFY2025 · Dec 31, 2025Net Income
-236.93MUSDFY2025 · Dec 31, 2025EBIT
-233.58MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-233.37MUSDFY2025 · Dec 31, 2025Research & Development
181.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
60.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.34MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.22MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.45USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.45USDFY2025 · Dec 31, 2025Basic Shares Outstanding
163.39MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
163.39MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-236.93MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-205.57MUSDFY2025 · Dec 31, 2025Free Cash Flow
-205.79MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
182.53MUSDFY2025 · Dec 31, 2025Income Tax Paid
323.00KUSDFY2025 · Dec 31, 2025Interest Paid
1.50MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-236.93MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
208.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
29.88MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.13MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
71.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.93MUSDFY2025 · Dec 31, 2025Capital Expenditures
218.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-82.87MUSDFY2025 · Dec 31, 2025Sale of Investments
251.17MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
168.52MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
57.16MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
76.81MUSDFY2025 · Dec 31, 2025Shares Outstanding
185.28MSharesUpdated Sep 28, 2026Float Shares
116.36MSharesUpdated Sep 28, 2026Shares Short
6.98MSharesUpdated Sep 28, 2026Short Ratio
8.79daysvs all stocks
Short % of Shares Outstanding
6.35%vs all stocks
% Held by Insiders
23.25%vs all stocks
% Held by Institutions
60.12%vs all stocks
Total Cash (MRQ)
116.83MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6220USDUpdated Sep 28, 2026Total Debt (MRQ)
53.25MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.20xvs Biotechnology peers
Current Ratio (MRQ)
4.50xvs Biotechnology peers
Book Value per Share (MRQ)
0.2380USDUpdated Sep 28, 2026Total Assets
191.05MUSDvs all stocks (USD)
Total Current Assets
190.54MUSDFY2025 · Dec 31, 2025Total Liabilities
87.18MUSDFY2025 · Dec 31, 2025Total Non-current Assets
510.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
54.73MUSDFY2025 · Dec 31, 2025Total Current Liabilities
32.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
182.53MUSDFY2025 · Dec 31, 2025Other Short-term Investments
0.00USDFY2025 · Dec 31, 2025Accounts Payable
3.38MUSDFY2025 · Dec 31, 2025Short-term Debt
284.00KUSDFY2025 · Dec 31, 2025Long-term Debt
54.73MUSDFY2025 · Dec 31, 2025Common Stock (Book)
17.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.18BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
103.87MUSDvs all stocks (USD)
52-Week Low
0.6330USDUpdated Sep 28, 202652-Week High
3.65USDUpdated Sep 28, 202652-Week Change
-61.48%vs all stocks
Beta
2.74xvs all stocks
50-Day MA
1.37USDUpdated Sep 28, 2026200-Day MA
1.96USDUpdated Sep 28, 2026Avg 10-Day Volume
2.28MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.29MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.23USDUpdated Sep 28, 2026Other Income / Expense
-767.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -187.1%, lower than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: -1.87Industry median: -0.22Industry P5: -1.57Peers compared: 260
Debt-to-equity is 1.2×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 1.20Industry median: 0.07Industry P95: 0.93Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $127.32M, lower than 95% of all stocks globallySignificant
Market cap (USD): 127,318,275Global P5: 275,556,405.438
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curacle Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Scancell Holdings Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Futurechem Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Md Entertainment Tbk
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Wintao Communications Co.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated